Clincosm LogoSign in Get a demo

Ghrelin: The Effects of the Endocrine System on Endometrial Cancer

Sponsor
Queensland Centre for Gynaecological Cancer (Other)
Overall Status
Completed
CT.gov ID
NCT01075386
Collaborator
Greenslopes Private Hospital (Other), The University of Queensland (Other), Sullivan and Nicolaides Pathology (Other)
75
Enrollment
1
Location
110
Actual Duration (Months)
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    75 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer
    Actual Study Start Date :
    Oct 1, 2009
    Actual Primary Completion Date :
    Aug 1, 2011
    Actual Study Completion Date :
    Dec 1, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Grade 2

    Patients with Endometrial cancer of Grade 1 differentiation
    Benign

    Patients without endometrial cancer
    Grade 1

    Patients with Endometrial cancer of Grade 2 differentiation
    Grade 3

    Patients with Endometrial cancer of Grade 3 differentiation

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      Female
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:

      • women aged 18 years or older

      • having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding

      • have provided informed consent

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Greenslopes Private Hospital Greenslopes Queensland Australia 4120

      Sponsors and Collaborators

      • Queensland Centre for Gynaecological Cancer
      • Greenslopes Private Hospital
      • The University of Queensland
      • Sullivan and Nicolaides Pathology

      Investigators

      • Study Chair: Chen Chen, MD PhD, The University of Queensland

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Queensland Centre for Gynaecological Cancer
      ClinicalTrials.gov Identifier:
      NCT01075386
      Other Study ID Numbers:
      • Endo01
      First Posted:
      Feb 25, 2010
      Last Update Posted:
      Aug 28, 2019
      Last Verified:
      Aug 1, 2019
      Keywords provided by Queensland Centre for Gynaecological Cancer
      Hysterectomy
      Endometrial cancer
      Benign
      Endocrine system
      Tissue collection
      Additional relevant MeSH terms:
      Endometrial Neoplasms

      Study Results

      No Results Posted as of Aug 28, 2019